Join
Live feed
·
PRReleasevia Quantisnow
Eupraxia Pharmaceuticals Inc. logo

Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis

ByQuantisnow·Wall Street's wire, on your screen.
EPRX· Eupraxia Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EPRX (Eupraxia Pharmaceuticals Inc.) and more on Quantisnow.